|Day Low/High||2.39 / 2.50|
|52 Wk Low/High||1.19 / 4.42|
Results Demonstrate IMO-2125 plus ipilimumab combination is tolerable at all dose levels studied and has demonstrated durable clinical activity in PD-1 Refractory Melanoma
The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 2,502,803 share decrease in total short interest for Idera Pharmaceuticals Inc , to 8,361,439, a decrease of 23.04% since 12/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Idera receives $15 million upfront, with potential IMO-9200-related milestone payments totaling up to $140 million plus royalties
Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.
Insiders at these companies are scooping up shares of their own stock lately.
Presentation to be made at Cold Springs Harbor Laboratory Conference on Regulatory & Non-Coding RNAs
Investors considering a purchase of Idera Pharmaceuticals Inc shares, but tentative about paying the going market price of $2.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $1 strike, which has a bid at the time of this writing of 10 cents.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.